891. Randomized, Double-Blind, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of Intravenous Iclaprim (ICL) versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia Suspected or Confirmed Caused by Gram-positive Pathogens
Session: Poster Abstract Session: Clinical Trials
Friday, October 9, 2015
Room: Poster Hall
  • 891_IDWPOSTER.pdf (364.5 kB)
  • Background: ICL, a new generation diaminopyrimidine compound, is a dihydrofolate reductase inhibitor antibiotic in clinical development. The primary objective of the study was to compare the clinical cure rates of ICL dosing regimens of 0.8 mg/kg q12h and 1.2 mg/kg q8h with vancomycin 1 g q12h in the treatment of patients with nosocomial pneumonia suspected or confirmed to be caused by Gram-positive pathogens.

    Methods: This was a double-blind, randomized, multicenter Phase 2 study. Patients were randomized 1:1:1 to ICL 0.8 mg/kg q12h, ICL 1.2 mg/kg q8h, or vancomycin 1 g q12h for 7-21 days, and were evaluated daily during their treatment course and at EOT, TOC (7–14 days post treatment), and LFU (7–14 days after the TOC visit) visits. The primary efficacy endpoint was the proportion of patients achieving a clinical cure at TOC based on investigator assessment. A key secondary endpoint was the proportion of patients who died within 28 days after the start of treatment.

    Results: A total of 70 patients were randomized and treated, including 23, 24 and 23 who received ICL 0.8 mg/kg q12h, ICL 1.2 mg/kg q8h, and vancomycin 1g q12h, respectively. Demographic characteristics were comparable across treatments. 30% of patients had a baseline pathogen identified: S. aureus in 15 patients, S. pneumoniae in 5 patients, and S. agalactiae, β-hemolytic Group C, and β-hemolytic Group F streptococcus in 1 patient each. Cure rates were higher for the ICL groups than for the vancomycin group with 73.9%, 62.5%, and 52.2% of ITT patients achieving cure at the TOC visit in the 0.8 mg/kg q12h, 1.2 mg/kg q8h ICL, and vancomycin groups, respectively.  The death rates within 28 days of the start of treatment were 8.7% and 12.5% for the ICL 0.8 mg/kg q12h and ICL
1.2 mg/kg q8h groups, respectively, and 21.7% in the vancomycin group. The adverse event profile of ICL was comparable with that of vancomycin. Overall, 55 of the 70 patients reported TEAEs; 82.6%, 70.8%, and 82.6% of patients in the 0.8 mg/kg q12h ICL, 1.2 mg/kg q8h ICL, and vancomycin treatment groups, respectively.

    Conclusion: ICL showed high clinical cure rates and a good safety profile among patients with nosocomial pneumonia, which were comparable with those achieved by vancomycin. ICL could be an important new therapeutic option for treatment of nosocomial pneumonia. A pivotal clinical trial is warranted to evaluate ICL for this indication.

    David Huang, MD, PhD, Motif BioSciences, New York, NY, Mark Wilcox, MD, Microbiology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, Paul Hadvary, PhD, Formerly Arpida AG, CH, Reinach, Switzerland and Ralph Corey, MD, Duke University Medical Center, Durham, NC


    D. Huang, Motif BioSciences: Employee , Salary

    M. Wilcox, Motif BioSciences: Consultant , Scientific Advisor and Shareholder , Consulting fee
    Pfizer: Consultant , Scientific Advisor and Speaker's Bureau , Consulting fee and Speaker honorarium
    Durata: Consultant and Scientific Advisor , Consulting fee
    Cerexa: Consultant and Scientific Advisor , Consulting fee and Speaker honorarium
    Paratek: Consultant and Scientific Advisor , Consulting fee
    Nabriva: Consultant and Scientific Advisor , Consulting fee

    P. Hadvary, None

    R. Corey, Motif BioSciences: Consultant , Consulting fee

    See more of: Clinical Trials
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.